Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

International, Multi-Center, Open-label, Treatment Extension Study of Iniparib as Monotherapy or in Combination Chemotherapeutic Regimens in Cancer Patients Who Have Derived Clinical Benefit From Iniparib Following Completion of a Phase 1, 2 or 3 Parental Study

NCT01593228 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01593228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01593228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
International, Multi-Center, Open-label, Treatment Extension Study of Iniparib as Monotherapy or in Combination Chemotherapeutic Regimens in Cancer Patients Who Have Derived Clinical Benefit From Iniparib Following Completion of a Phase 1, 2 or 3 Parental Study
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2012
Completion date
September 30, 2016
Enrollment
37 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors